Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > ARCHIVE
ARCHIVE
- Healthcare Reform Proposals Expected No Sooner Than Fall
February 26, 2001
- Welfide Licenses Agent for Diabetic Neuropathy to Takeda
February 26, 2001
- Additional Indications Required to Commercialize Artificial Erythrocytes
February 26, 2001
- Fujisawa Launches Protopic in US
February 26, 2001
- Aventis Behring Launches Web Site
February 26, 2001
- Worldwide Sales of Yakult's Irinotecan to Top \150 Bil. in 2005
February 26, 2001
- Council Starts Discussions to Improve Drug Information Supply System
February 26, 2001
- Kyorin, Ono to Codevelop Drug for Urinary Incontinence
February 26, 2001
- METI Report Calls For Free Competition for Medical, Nursing Care Services
February 26, 2001
- BUSINESS NEWS IN BRIEF -1-
February 26, 2001
- Elimination of NHI Price SystemShould Be Considered: Prof. Tokita
February 26, 2001
- REGULATORY NEWS IN BRIEF
February 26, 2001
- WORLD BUSINESS NEWS IN BRIEF
February 26, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 26, 2001
- New Law Specific for Medical Devices Is Necessary: JFITMA President
February 26, 2001
- Kirin to Sponsor Genomic Medical Engineering Course at Tottori Univ.
February 26, 2001
- New ARIA Guidelines Prepared by WHO for Allergic Rhinitis
February 26, 2001
- Delisting Should Be Considered for Certain Drugs: Finance Ministry Officer
February 19, 2001
- Nihon Nosan Kogyo Forms Alliance with PPL Therapeutics of UK for Genomic Technology
February 19, 2001
- Japan, EU Mutual GMP Recognition Coming Soon
February 19, 2001
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…